Methylglyoxal synthase (MGS)

Methylglyoxal synthase is an enzyme found primarily in prokaryotes such as bacteria, where it catalyzes the conversion of dihydroxyacetone phosphate (DHAP), a glycolytic intermediate, to methylglyoxal and inorganic phosphate[1][3][5][6]. It functions as an alternative catabolic pathway under phosphate-limited conditions, serving to manage cellular phosphate levels and providing a mechanism for cells to continue glycolysis when phosphate is scarce[1]. Methylglyoxal is a highly reactive and cytotoxic compound, thus organisms possessing methylglyoxal synthase must have robust downstream detoxification pathways (such as glyoxalase) to prevent cellular damage[2][4][9]. The enzyme is structurally a homohexamer and mechanistically distinct from the related triosephosphate isomerase, catalyzing phosphate elimination rather than isomerization[3][7]. While not directly therapeutically targeted in humans, methylglyoxal synthase plays roles in bacterial physiology relevant to infection, stress response, and industrial fermentation; its gene deletion or modification has been leveraged to improve microbial production of biofuels and chemicals[1][5]. Methylglyoxal synthase is not typically associated with specific human diseases but may be a hypothetical antimicrobial target since inhibition could impact pathogenic bacteria’s stress tolerance or metabolic flexibility.

Catalytic elimination of phosphate from dihydroxyacetone phosphate to form methylglyoxal[3][7] Targeting would modulate intracellular methylglyoxal production and downstream metabolic flow